Stockreport

HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

HilleVax, Inc.  (HLVX) 
PDF Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of M [Read more]